at Zacks.com (Oct 30, 2014)
Synergy Pharmaceuticals (SGYP +10.3%) soars on heavy volume after Cantor Fitzgerald raises its price target on the shares to $15 from $12. Irina Rivkind says the company's lead investigational drug plecanatide can "achieve revenue parity" with Ironwood (IRWD -0.5%) and Forest Laboratories' (FRX -0.2%) Linzess, an FDA approved treatment for constipation.
From other sites
at MarketWatch.com (Jan 2, 2013)
at Fox Business (Aug 30, 2012)
at MarketWatch.com (May 4, 2012)